Notice: Function Elementor\Controls_Manager::add_control_to_stack was called incorrectly. Cannot redeclare control with same name "eael_image_masking_upload_pro_message". Please see Debugging in WordPress for more information. (This message was added in version 1.0.0.) in /data/vhosts/livinginsilico.ca/livinginsilico.ca/wp-includes/functions.php on line 6121
The gold-standard treatment for Parkinson’s is administration of Levodopa (L-Dopa). The delivery of this medication has recent innovations including a procedure has been developed delivering it directly to the source by stimulating the brain-lymphatic vasculature, increasing function of dopaminergic neurons.
Other therapy methods include transcranial alternating current stimulation (tACS), transcranial electrical stimulation (tES), neuromodulation, noninvasive brain stimulation (NIBS), neuroplasticity, neural entrainment, non-invasive transcranial brain stimulation (NTBS). Each method mentioned has proven to be effective in increasing neuronal excitability, however, has not proven to provide any significant long-term change in treatment of the disorder. Per results, long-term administration would theoretically gradually increase efficacy in treatment, however, exposure to these devices long-term is unadvised due to safety concerns.
- Sohini Ghosh
Summary:
- Neuron excitability, through non-invasive intervention is presided by supplemental administration of dopamine as L-DOPA and their derivatives.
- Brain-lymphatic vasculature stimulation as a procedure increased functional dopaminergic neurons within preclinical animal models.
- Long-term therapies of transcranial electrical stimulation and neural sensescape therapies increase plasticity towards baseline neuronal excitability.
Conclusion:
There is viable application of co-treatment with gold standard L-DOPA before and during additional non-invasive treatments for increasing dopaminergic neurons.
